Telix Reports Third Quarter 2022 Financial Results
prnewswire.com
news
2022-10-19 22:06:00

MELBOURNE, Australia, Oct. 19, 2022 /PRNewswire/ --Â Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis.
Financial Summary

Telix reports total revenue of $55.3 million from global sales of Illuccix, up 168% on the previous quarter ($20.6 million, Q2 2022)
U.
